Skip to main content
. 2019 Feb 12;14(2):e0212278. doi: 10.1371/journal.pone.0212278

Table 1. Baseline characteristics.

All Patients
(n = 2898)
hsTnT ≤ 14 ng/L
(n = 1267)
hsTnT > 14 ng/L
(n = 1631)
P-Value
Age (years) 74 [66–81] 69 [59–75] 78 [71–84] < 0.001
Male sex 1704/2898 (58.8) 699/1267 (55.2) 1005/1631 (61.6) <0.001
Diabetes mellitus 785/2887 (27.2) 222/1263 (17.6) 563/1624 (34.7) < 0.001
Arterial hypertension 2368/2884 (82.1) 952/1263 (75.4) 1416/1621 (87.4) < 0.001
Prior stroke or transient ischemic attack 298/2887 (10.3) 89/1265 (7.0) 209/1622 (12.9) < 0.001
Peripheral artery disease 237/2886 (8.2) 49/1264 (3.9) 188/1622 (11.6) < 0.001
Coronary artery disease 1322/2880 (45.9) 420/1262 (33.3) 902/1618 (55.7) < 0.001
Prior myocardial infarction 501/2885 (17.4) 116/1264 (9.2) 385/1621 (23.8) < 0.001
Prior percutaneous coronary intervention 604/2878 (21.0) 189/1264 (15.0) 415/1615 (25.7) < 0.001
Prior coronary artery bypass surgery 277/2886 (9.6) 60/1264 (4.7) 217/1622 (13.4) < 0.001
Reduced ejection fraction (moderately or severely, < 45%) 601/1787 (33.6) 115/669 (17.2) 486/1118 (43.5) < 0.001
Valvular atrial fibrillation 186/2475 (7.5) 38/1102 (3.4) 148/1373 (10.8) < 0.001
Atrial fibrillation in admission electrocardiogram (ECG) 2628/2891 (90.9) 1110/1265 (87.7) 1518/1626 (93.4) < 0.001
Estimated glomerular filtration rate (eGFR)* (mL/min/1.73 m2) 71 [51–88] 82 [67–97] 59 [41–79] < 0.001
Severely impaired renal function (eGFR < 30 mL/min/1.73 m2) 208/2888 (7.2) 8/1260 (0.6) 200/1628 (12.3) < 0.001
Liver cirrhosis 25/2884 (0.9) 9/1265 (0.7) 16/1619 (1.0) 0.553
Aspartate transaminase (AST) (IU/L) 27 [20–37] 25 [20–33] 28 [21–42] < 0.001
Aspartate transaminase (AST) > 2 x upper limit of normal (ULN) 138/2863 (4.8) 32/1254 (2.6) 106/1609 (6.6) < 0.001
Prior major bleeding 146/2875 (5.1) 36/1265 (2.8) 110/1610 (6.8) < 0.001

Data are median [25th, 75th percentiles] or number of patients (%)

* By Modification of Diet in Renal Disease (MDRD) equation